2024
Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease
Srivastava S, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, Rajendran B, Setia O, Aryal B, Kanasaki K, Koya D, Inoki K, Dardik A, Bell T, Fernández-Hernando C, Shulman G, Goodwin J. Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease. Science Advances 2024, 10: eadn6068. PMID: 39630889, PMCID: PMC11616692, DOI: 10.1126/sciadv.adn6068.Peer-Reviewed Original ResearchMeSH KeywordsAngiopoietin-Like Protein 4AnimalsDiabetes Mellitus, ExperimentalDiabetic NephropathiesDisease Models, AnimalEpithelial-Mesenchymal TransitionFibrosisHumansIntegrin beta1KidneyMicePodocytesConceptsAngiopoietin-like 4Diabetic kidney diseaseIntegrin B1Fibrogenic moleculesMutant miceSTING pathway activationIncreased fatty acid oxidationProgressive diabetic kidney diseaseDiabetic kidneyKidney diseaseReduced epithelial-to-mesenchymal transitionEpithelial-to-mesenchymal transitionFatty acid oxidationExpression of pro-inflammatory cytokinesTargeted pharmacological therapiesGene expressionMitochondrial damageEndothelial-to-mesenchymal transitionPro-inflammatory cytokinesPathway activationPharmacological therapyControl miceIntegrinAcid oxidationFibrogenic phenotype
2014
Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis
Perry RJ, Zhang XM, Zhang D, Kumashiro N, Camporez JP, Cline GW, Rothman DL, Shulman GI. Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nature Medicine 2014, 20: 759-763. PMID: 24929951, PMCID: PMC4344321, DOI: 10.1038/nm.3579.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlood GlucoseDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1GlucagonGluconeogenesisHypothalamo-Hypophyseal SystemInsulinLeptinLipolysisPituitary-Adrenal SystemRats
2000
Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice
Gavrilova O, Marcus-Samuels B, Graham D, Kim J, Shulman G, Castle A, Vinson C, Eckhaus M, Reitman M. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. Journal Of Clinical Investigation 2000, 105: 271-278. PMID: 10675352, PMCID: PMC377444, DOI: 10.1172/jci7901.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueAnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, LipoatrophicFatty AcidsGene Expression RegulationGene Transfer TechniquesInsulin ResistanceMiceTriglyceridesConceptsA-ZIP/FLipoatrophic diabetesAdipose tissueNear-physiological amountsMuscle insulin sensitivityLack of fatLipoatrophic miceInsulin levelsHepatic steatosisInsulin resistanceInsulin sensitivitySevere formFFA levelsDiabetesDonor fatTransplantationBeneficial effectsEndocrine communicationSubcutaneous sitesMiceSurgical implantationAdipose physiologyHyperglycemiaFatTissue
1990
Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations
Rossetti L, DeFronzo R, Gherzi R, Stein P, Andraghetti G, Falzetti G, Shulman G, Klein-Robbenhaar E, Cordera R. Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations. Metabolism 1990, 39: 425-435. PMID: 2157941, DOI: 10.1016/0026-0495(90)90259-f.Peer-Reviewed Original ResearchConceptsInsulin receptor tyrosine kinase activityDiabetic ratsMetformin treatmentReceptor tyrosine kinase activityTyrosine kinase activitySupernormal levelsGlucose disposalInsulin-mediated whole-body glucose disposalTotal body insulin-mediated glucose disposalInsulin actionNeonatal streptozotocin diabetic ratsTotal body glucose uptakeInsulin-mediated glucose disposalWhole-body glucose disposalGlucose uptakeDeficient insulin responseNormalized glucose toleranceInsulin clamp studiesStreptozotocin-diabetic ratsVivo insulin actionHepatic glucose productionMuscle glycogen synthesisGlycogen synthesisSynthetic rateGlucose tolerance